Top Markets
#1 Cortex Cortex +32.42%
#2 龙虾 (Lobster) 龙虾 (Lobster) +30.38%
#3 Akedo Akedo +25.48%
#4 DexNet DexNet +23.19%
#5 Pons Pons +21.68%
#6 wojak wojak +16.75%
#7 APEX APEX +13.93%
#8 OpenEden OpenEden +13.55%
#9 Official Trump Official Trump +11.37%
#10 EXOD EXOD +9.04%
Coin of the day
Cortex Cortex
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Classifica tra le azioni #7110
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Prezzo delle azioni
$99.16
Ultima sincronizzazione: 2026-08-27
Capitalizzazione di mercato
$1.72B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
2.52%
Paese
ES
Scambia Pharma Mar, S.A. (PHM)

Categoria

Healthcare
Ricavi di Pharma Mar, S.A. (PHM)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Pharma Mar, S.A., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Pharma Mar, S.A. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH